DeepMed Research

INJE UNIVERSITY

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1979-01-01

Employees: 51

Market Cap: -

Website: http://www.inje.ac.kr

Clinical Trials

Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial

Phase 3

Completed

Conditions: Bowel Preparation, Efficacy, Tolerability, Safety

Interventions: Drug: Sodium phosphate(NaP) solution
Drug: Polyethylene glycol

First Posted Date: 2010-10-28

Last Posted Date: 2010-10-28

Lead Sponsor: Inje University

Target Recruit Count: 207

Registration Number: NCT01229800

Locations: 🇰🇷
Inje University School of Medicine, Haeundae Paik Hospital, Busan, Korea, Republic of

Tamoxifen Pharmacogenetics in Asian Breast Cancer Women

Conditions: Poisoning by, Adverse Effect of and Underdosing of Tamoxifen

First Posted Date: 2010-08-13

Last Posted Date: 2013-06-03

Lead Sponsor: Inje University

Target Recruit Count: 1000

Registration Number: NCT01181518

Locations: 🇰🇷
Inje University, Busan, Korea, Republic of

STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study

Phase 1

Completed

Conditions: Genotype Guided(HNF4a)
Healthy Subjects

Interventions: Drug: Tolterodine

First Posted Date: 2010-08-13

Last Posted Date: 2010-08-13

Lead Sponsor: Inje University

Target Recruit Count: 31

Registration Number: NCT01181505

PGx Study to Develop and Validate the Predictive Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy

Completed

Conditions: Heart Valve Diseases

First Posted Date: 2010-08-10

Last Posted Date: 2013-06-03

Lead Sponsor: Inje University

Target Recruit Count: 405

Registration Number: NCT01178502

Locations: 🇰🇷
Inje University, Busan, Korea, Republic of

The Clinical Course of Coronary Artery Disease in Coronary Multidetector Computed Tomographic Angiogram

Conditions: Cardiovascular Diseases
Atherosclerosis
Coronary Artery Disease

First Posted Date: 2010-06-14

Last Posted Date: 2010-09-13

Lead Sponsor: Inje University

Target Recruit Count: 5000

Registration Number: NCT01142973

Locations: 🇰🇷
Ilsan Paik hospital, Goyang, Korea, Republic of

BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)

Phase 2

Conditions: Non Hodgkin's Lymphoma

Interventions: Drug: Busulfan, Etoposide, Cytarabine, Melphalan

First Posted Date: 2010-02-05

Last Posted Date: 2010-12-02

Lead Sponsor: Inje University

Target Recruit Count: 42

Registration Number: NCT01063439

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of
🇰🇷
Yeonsei University Hospital, Seoul, Korea, Republic of

and more 2 locations

Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control

Completed

Conditions: Pain, Postoperative

First Posted Date: 2009-01-19

Last Posted Date: 2013-06-04

Lead Sponsor: Inje University

Target Recruit Count: 204

Registration Number: NCT00824772

Locations: 🇰🇷
Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of

The Efficacy and Safety of Dexibuprofen Syrup

Phase 3

Completed

Conditions: Fever
Respiratory Tract Infection

Interventions: Drug: Dexibuprofen
Drug: Ibuprofen

First Posted Date: 2008-12-22

Last Posted Date: 2010-01-18

Lead Sponsor: Inje University

Target Recruit Count: 260

Registration Number: NCT00812422

Locations: 🇰🇷
Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of

and more 1 locations

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Phase 4

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: adefovir
Drug: lamivudine
Drug: clevudine

First Posted Date: 2008-11-26

Last Posted Date: 2011-06-23

Lead Sponsor: Inje University

Target Recruit Count: 30

Registration Number: NCT00798460

Locations: 🇰🇷
Ilsanpaik hospital, Goyang, Gyunggi, Korea, Republic of

The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

Phase 1

Completed

Conditions: Pharmacokinetics of Three PDE5Is
Healthy Subjects
Genetic Polymorphic CYP3A5

Interventions: Drug: phosphodiesterase type 5 inhibitor

First Posted Date: 2008-10-07

Last Posted Date: 2008-10-07

Lead Sponsor: Inje University

Target Recruit Count: 21

Registration Number: NCT00767598

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy